Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

223.99 +3.81 (+1.73%)
Streaming Delayed Price Updated: 3:10 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
91 92 Next >
Top S&P500 movers in Monday's session ↗
Via Chartmill
News headline image
Flu Season's Here—This Dividend-Payer Controls the Shot Market ↗
Via MarketBeat
Topics Artificial Intelligence Death
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
News headline image
26 Top Dividend Stocks to Buy and Hold in 2026 ↗
Another year, another long list of great dividend stocks. 
Via The Motley Fool
Topics Intellectual Property
News headline image
GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment ↗
GH001 showed symptom improvement, high remission rates, and sustained benefits in a Phase 2b trial for treatment-resistant depression. 
Via Stocktwits
News headline image
Take Warren Buffett's Advice: Don't Buy Any Stock in 2026 Unless It Passes This Test ↗
Buffett is no longer at the helm of Berkshire Hathaway. But his investing wisdom remains relevant. 
Via The Motley Fool
News headline image
Buying This Healthcare Stock Could Make You a Millionaire Retiree ↗
It won't happen overnight, but patience will be rewarded. 
Via The Motley Fool
Topics Intellectual Property Retirement
News headline image
The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature
As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has... 
Via PredictStreet
Topics Economy Lawsuit World Trade
News headline image
The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings
As 2025 draws to a close, the pharmaceutical industry stands at a historic crossroads. The year was defined by a widening chasm between the "metabolic haves"—those profiting from the global obesity... 
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
News headline image
The Great Rebalancing: As Consumer Confidence Falters, Investors Retreat to the Safety of Large-Cap Value
As the curtain closes on 2025, the exuberant "risk-on" sentiment that defined the early years of the artificial intelligence boom has been replaced by a somber, calculated retreat. On this final day of... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
AbbVie (ABBV): Buy, Sell, or Hold Post Q3 Earnings?
AbbVie has had an impressive run over the past six months as its shares have beaten the S&P 500 by 12.4%. The stock now trades at $229.70, marking a 23.7% gain. This performance may have investors... 
Via StockStory
Topics Stocks Supply Chain
News headline image
IGSB vs VCSH: Two Approaches to Short-Term Investment-Grade Credit ↗
Both ETFs target short-term investment-grade bonds, but their construction determines how visible credit risk becomes when spreads move. 
Via The Motley Fool
Topics Bonds ETFs
News headline image
3 No-Brainer Dividend Stocks to Buy Right Now ↗
You don't need to settle for an average dividend yield. 
Via The Motley Fool
Topics ETFs Retirement
News headline image
The 2026 Income Fortress: Why Big Pharma is the Defensive Play of the New Year
As the sun sets on 2025, investors are increasingly pivoting toward the pharmaceutical sector, seeking a "defensive income fortress" to weather potential macroeconomic volatility in 2026. The... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Why a New $3 Million Bet on Pathward Stock Signals Confidence in a Bank Posting $7.87 EPS ↗
After a year of steady execution and profitability, Pathward is perhaps starting to look less like a niche lender and more like a quietly scalable earnings machine. 
Via The Motley Fool
News headline image
Is AbbVie a Buy, Sell, or Hold in 2026? ↗
It is wrapping up another great year, and there is no sign of a slowdown. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Best Stocks to Invest $50,000 in Right Now ↗
If you're investing for the long run, there are a myriad of companies begging to be bought. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
The Vaccine Vanguard: Inside Sanofi’s $2.2 Billion Strategic Bet on Dynavax
As 2025 draws to a close, the global pharmaceutical landscape has been reshaped by a series of aggressive consolidations and strategic pivots. At the center of this transformation is Sanofi (NASDAQ:... 
Via PredictStreet
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Top 5 US Healthcare Stocks By Market Value ↗
Weight-loss drugs, drug-pricing reforms, and legal challenges have reshaped the U.S. healthcare landscape in 2025. 
Via Stocktwits
News headline image
The Next Big Buyout? Abivax Emerges as a Premier M&A Contender for 2026 Amidst Biotech Consolidation Wave
As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (NASDAQ: ABVX). Following a year of stellar clinical results... 
Via MarketMinute
Topics Intellectual Property
News headline image
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever ↗
Investors can expect steady dividend returns with these stocks. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Dividend Growth Stocks Analysts Are Upgrading for 2026 ↗
Via MarketBeat
News headline image
AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report ↗
This comes after President Donald Trump urged drugmakers in July to lower drug prices for the U.S. government’s Medicaid program. 
Via Stocktwits
Topics Economy Government
News headline image
This Is the 2nd Priciest Stock Market in 155 Years, Which Makes This High-Yield ETF a Genius Buy for 2026 ↗
This top-shelf exchange-traded fund (ETF) checks all the right boxes for income- and value-seeking investors. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
Want $10,000 in Passive Income? This Vanguard ETF Could Be Your Ticket to Making It Happen. ↗
Investors would need to have over $330,000 invested in this Vanguard dividend ETF. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Is AbbVie a Millionaire Maker? ↗
AbbVie's third-quarter earnings were disappointing, but the company raised its full-year guidance and increased the dividend. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Worried About the Stock Market in 2026? These 3 Stocks Did Well During the Last Bear Market. ↗
The stocks listed here were all up more than 19% in 2022, while the S&P 500 crashed. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
The Yield Search: Why Retirees are Swapping Growth for Defense in a Shifting 2025 Market
As of December 18, 2025, the financial landscape is undergoing a significant transformation, forcing retirees to reconsider their high-octane growth strategies in favor of more stable,... 
Via MarketMinute
Topics Artificial Intelligence Bonds ETFs
Want Decades of Passive Income? Buy This ETF and Hold It Forever. ↗
Can one ETF deliver decades of dividend income? This unique high-quality yield generator deserves a spot on your watchlist. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗
The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing. 
Via Stocktwits
Topics Government World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
91 92 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.